HELP     Sign In
Search

Relevance to Autism

Rare variants in the EIF4E gene have been identified with autism (Neves-Pereira et al., 2009).

Molecular Function

Translation initiation factor involved in directing ribosomes to the cap structure of mRNAs

External Links

        

References

Type
Title
Type of Disorder
Associated Disorders
Author, Year
Primary
Deregulation of EIF4E: a novel mechanism for autism.
ASD
Positive Association
Common EIF4E variants modulate risk for autism spectrum disorders in the high-functioning range.
ASD
Support
Dysregulated acetylcholine-mediated dopamine neurotransmission in the eIF4E Tg mouse model of autism spectrum disorders
ASD
Support
The Overexpression of eIF4E Decreases Oxytocin Levels and Induces Social Cognitive Behavioral Disorders in Mice
ASD
Support
Integrating de novo and inherited variants in 42
ASD
Support
Genome-wide characteristics of de novo mutations in autism
ASD
Support
High-throughput sequencing of mGluR signaling pathway genes reveals enrichment of rare variants in autism.
Non-syndromic ASD
Highly Cited
Tumstatin, an endothelial cell-specific inhibitor of protein synthesis.
Highly Cited
Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism.
Highly Cited
The mRNA 5' cap-binding protein eIF4E and control of cell growth.
Highly Cited
Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function.
Highly Cited
The translational repressor Pumilio regulates presynaptic morphology and controls postsynaptic accumulation of translation factor eIF-4E.
Recent Recommendation
Exaggerated translation causes synaptic and behavioural aberrations associated with autism.
Recent Recommendation
Role of the phosphoinositide 3-kinase-Akt-mammalian target of the rapamycin signaling pathway in long-term potentiation and trace fear conditioning...
Recent Recommendation
eIF4E function in somatic cells modulates ageing in Caenorhabditis elegans.

Rare

Variant ID
Variant Type
Allele Change
Residue Change
Inheritance Pattern
Inheritance Association
Family Type
Author, Year
 GEN077R001 
 translocation 
  
  
 De novo 
  
 Simplex 
 GEN077R002 
 2KB_upstream_variant 
 c.-25insC 
  
 Familial 
 Paternal 
 Multiplex 
 GEN077R003 
 2KB_upstream_variant 
 c.-25insC 
  
 Familial 
 Paternal 
 Multiplex 
 GEN077R004 
 intron_variant 
 c.540-10T>G 
  
  
  
 Multiplex 
 GEN077R005 
 missense_variant 
 c.194A>T 
 p.Lys65Met 
 De novo 
  
 Simplex 
 GEN077R006 
 missense_variant 
 c.272A>G 
 p.Tyr91Cys 
 De novo 
  
  

Common

Variant ID
Polymorphism
SNP ID
Allele Change
Residue Change
Population Origin
Population Stage
Author, Year
 GEN077C001 
 intron_variant 
 rs13109000 
 c.186-3048A>G;c.126-3048A>G;c.210-3048A>G 
  
 708 German ASD families; 605 individuals diagnosed with strict autism, subgroup of 369 individuals in high-functioning strict autism range (HFA) 
 Discovery 
 GEN077C002 
 intron_variant 
 rs4699369 
 c.282-319C>T;c.222-319C>T;c.306-319C>T 
  
 708 German ASD families; 605 individuals diagnosed with strict autism, subgroup of 369 individuals in high-functioning strict autism range (HFA) 
 Discovery 
 GEN077C003 
 intron_variant 
 rs12498533 
 c.185+4194T>G;c.125+4194T>G;c.209+4194T>G 
  
 708 German ASD families; 605 individuals diagnosed with strict autism, subgroup of 369 individuals in high-functioning strict autism range (HFA) 
 Discovery 
Chromosome
CNV Locus
CNV Type
# of studies
Animal Model
4
Duplication
 1
 
4
Deletion-Duplication
 13
 
4
Deletion-Duplication
 2
 
4
Duplication
 1
 
4
Deletion-Duplication
 12
 

M_EIF4E_1_TG_4EGI-1

Rescue Type: RESCUE-Pharmaceutical
Rescue Paradigm: 4EGI-1, an inhibitor of eIF4E/eIF4G interactions was used to block the synaptic and behavioral consequences of increased eIF4E expression in transgenic mice over-expressing EIF4E. 4EGI-1 dissolved in 100% DMSO was diluted in vehicle [0.5% (2- hydroxypropyl)--cyclodextrin and 1% DMSO in ACSF]. 4EGI-1 (20 M) or vehicle were infused over 1 min (0.5 L/min; Harvard Apparatus) in anesthetized mice through implanted cannulae.

M_EIF4E_1_TG_4EGI-1

Category
Entity
Effect on phenotype Qualification
Restored Treatment improves measured phenotype significantly
Refractory Treatment does not improve measured phenotype (was expected to do so)
Ameliorated Treatment provides partial correction or improvement of measured phenotype
No adverse effect Treatment does not affect the parameter adversely
Sustained effect Treatment has long term effect of restoration or amelioration, tested AFTER stopping administration (not applied for continuing long-term treatment) . Will be applied only where treatment has had restorative effects during administration or in the first battery of tests conducted.
No sustained effect Treatment has no long term of restoration or amelioration detectable, after stopping administration. Will be applied only where treatment has had restorative effects during administration or in the first battery of tests conducted.
Unexpected results Treats an unexpected phenotype
Side effect Exaggerates an unexpected phenotype
Experimental Paradigm
Age at Testing
Synaptic plasticity: striatal ltd1
Restored
Description: 4egi-1 normalized the enhanced striatal ltd observed in the eif4e transgenic mice
Exp Paradigm: Whole-cell patch clamp. males only.
 Whole-cell patch clamp
 26 months
Repetitive digging1
Ameliorated
Description: Transgenic mice treated with 4egi-1 exhibited a decrease in repetitive behavior during the marble burying task, which started on day four and persisted throughout day five
Exp Paradigm: Sample size is 22 mice. males only.
 Marble-burying test
 26 months
Social interaction1
Restored
Description: 4egi-1 rescued the social behavior deficits displayed by the eif4e transgenic mice in the three-chamber test, as they exhibited an increased interaction with a freely moving stranger mouse
Exp Paradigm: Reciprocal social interaction test. males only.
 Three-chamber social approach test
 26 months
Social approach1
Restored
Description: 4egi-1 rescued the social behavior deficits displayed by the eif4e transgenic mice in the three-chamber test, as they exhibited an increased preference for a non-specific stranger compared to a novel object
Exp Paradigm: Reciprocal social interaction test. males only.
 Three-chamber social approach test
 26 months
Cognitive flexibility1
Ameliorated
Description: Transgenic mice treated with 4egi-1 exhibited improved performance in the reversal phase of the y-maze test compared to untreated eif4e transgenic mice
Exp Paradigm: Water y-maze; morris water maze test. males only.- morris water maze test
 Morris water maze test
 26 months
Cognitive flexibility1
Ameliorated
Description: Transgenic mice treated with 4egi-1 exhibited improved performance in the reversal phase of the y-maze test compared to untreated eif4e transgenic mice
Exp Paradigm: Water y-maze; morris water maze test. males only.-water y-maze
 Water y-maze test
 26 months
Regulation of translation1
Restored
Description: Transgenic mice treated with 4egi-1 exhibited reduced puromycin-labeling of newly synthesized proteins, compared to untreated eif4e transgenic mice
Exp Paradigm: Puromycin was infused into the lateral ventricle of cannulated mice and newly synthesized proteins were labelled using sunset and de novo cap-dependent translation was observed. males only.
 Autoradiographic analysis
 26 months
Protein binding1
Restored
Description: Transgenic mice treated with 4egi-1 exhibited reduced binding of eif4e to eif4g in the brain, compared to untreated eif4e transgenic mice
Exp Paradigm: Transgenic brain tissue was used as sample. males only.
 Immunoprecipitation
 26 months
 Not Reported: Circadian sleep/wake cycle, Communications, Developmental profile, Emotion, Immune response, Maternal behavior, Motor phenotype, Neuroanatomy / ultrastructure / cytoarchitecture, Physiological parameters, Seizure, Sensory

M_EIF4E_1_TG

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
 Hyperactivity1
 Increased
Description: Eif4e transgenic mice show slight increase in total time spent moving and total distance travelled compared to controls
Exp Paradigm: Males only
 Partition test
 26 months
 General locomotor activity: ambulatory activity1
 Increased
Description: Eif4e transgenic mice show slight increase in total time spent moving and total distance travelled compared to controls
Exp Paradigm: Males only
 Partition test
 26 months
 Dendritic architecture: spine density1
 Increased
Description: Eif4e transgenic mice show increased dendritic spine density and a smaller spine volume compared to controls
Exp Paradigm: Dendritic spines were imaged using two-photon laser-scanning microscopy. males only.
 Immunohistochemistry
 26 months
 Synaptic plasticity: hippocampal ltd1
 Increased
Description: Eif4e transgenic mice exhibited enhanced mglur-ltd compared to wild-type littermates
Exp Paradigm: Males only
 Whole-cell patch clamp
 26 months
 Spontaneous post synaptic event frequency: excitatory currents1
 Increased
Description: Eif4e transgenic mice show an increase in the frequency but not amplitude of spontaneous synaptic excitatory mepsc events in layers ii/iii of acute mpfc slices, compared to controls. no changes were observed in layer v.
Exp Paradigm: Males only
 Whole-cell patch clamp
 26 months
 Spontaneous post synaptic event amplitude: inhibitory currents1
 Increased
Description: Eif4e transgenic mice show an increase in the amplitude, but not frequency, of inhibitory mipsc events in layers ii/iii of acute mpfc slices, compared to controls. no changes were observed in layer v.
Exp Paradigm: Males only
 Whole-cell patch clamp
 26 months
 Synaptic plasticity: striatal ltd1
 Increased
Description: Eif4e transgenic mice exhibited enhanced ltd compared to wild-type littermates
Exp Paradigm: Males only
 Whole-cell patch clamp
 26 months
 Self grooming: perseveration1
 Increased
Description: Eif4e transgenic mice show increased self-grroming compared to controls
Exp Paradigm: Males only
 Grooming behavior assessments
 26 months
 Repetitive digging1
 Increased
Description: Eif4e transgenic mice exhibited repetitive digging behavior in the marble burying test unlike control mice
Exp Paradigm: Males only
 Marble-burying test
 26 months
 Inanimate object preference1
 Increased
Description: Eif4e transgenic mice show preference for a novel inanimate object over a stranger mouse, compared to controls
Exp Paradigm: Novel object interaction test. males only.
 Novel object recognition test
 26 months
 Social interaction1
 Decreased
Description: Eif4e transgenic mice exhibited diminished reciprocal interactions with a freely moving stranger mouse, compared to controls
Exp Paradigm: Males only.
 Three-chamber social approach test
 26 months
 Social approach1
 Decreased
Description: Eif4e transgenic mice show reduced preference for a novel stranger compared to a novel inanimate object, compared to controls
Exp Paradigm: Males only.
 Three-chamber social approach test
 26 months
 Cognitive flexibility1
 Decreased
Description: Eif4e transgenic mice exhibited cognitive inflexibility in being impaired in locating the new platform positions compared to control mice
Exp Paradigm: Males only- morris water maze test
 Morris water maze test
 26 months
 Cued or contextual fear conditioning: extinction1
 Decreased
Description: Eif4e transgenic mice did not exhibit a significant reduction in freezing responses following extinction training as did control mice
Exp Paradigm: Males only
 Fear conditioning test
 26 months
 Cognitive flexibility1
 Decreased
Description: Eif4e transgenic mice exhibited cognitive inflexibility in being impaired in locating the new platform positions compared to control mice
Exp Paradigm: Males only-water y-maze
 Water y-maze test
 26 months
 Regulation of translation1
 Decreased
Description: Eif4e transgenic mice show increased de novo cap-dependent translation in the brain, compared to controls
Exp Paradigm: Puromycin was infused into the lateral ventricle of cannulated mice and newly synthesized proteins were labeled using sunset and de novo cap-dependent translation was observed. males only.
 Autoradiographic analysis
 26 months
 Protein binding1
 Increased
Description: Eif4e transgenic mice show increased binding of eif4e to eif4g in the brain, compared to controls
Exp Paradigm: Transgenic brain tissue was used as sample. males only.
 Immunoprecipitation
 26 months
 Targeted expression1
 Increased
Description: Eif4e transgenic mice show increased expression of eif4e in multiple brain regions including the prefrontal cortex, striatum, hippocampus and cerebral cortex, compared to controls
Exp Paradigm: Males only
 Western blot
 26 months
General characteristics1
 No change
 General observations
 26 months
Mortality/lethality1
 No change
 General observations
 P0
Anxiety1
 No change
 Elevated plus maze test
 26 months
Spatial learning1
 No change
 Morris water maze test
 26 months
Spatial learning1
 No change
 Water y-maze test
 26 months
Spatial reference memory1
 No change
 Morris water maze test
 26 months
Spatial reference memory1
 No change
 Water y-maze test
 26 months
Gene expression1
 No change
 Semi-quantitative pcr (qrt-pcr)
 26 months
Protein binding1
 No change
 Western blot
 26 months
Grip strength1
 No change
 Accelerating rotarod test
 26 months
Motor coordination and balance1
 No change
 Accelerating rotarod test
 26 months
Swimming ability1
 No change
 Morris water maze test
 26 months
Swimming ability1
 No change
 Water y-maze test
 26 months
Spontaneous post synaptic event amplitude: excitatory currents1
 No change
 Whole-cell patch clamp
 26 months
Spontaneous post synaptic event frequency: inhibitory currents1
 No change
 Whole-cell patch clamp
 26 months
Reproductive function1
 No change
 General observations
 26 months
Vertical jumping or back flipping1
 No change
 Partition test
 26 months
Sensorimotor gating1
 No change
 Prepulse inhibition
 26 months
Startle response: acoustic stimulus1
 No change
 Acoustic startle reflex test
 26 months
 Not Reported: Circadian sleep/wake cycle, Communications, Immune response, Maternal behavior, Physiological parameters, Seizure


Interactor Symbol Interactor Name Interactor Organism Entrez ID Uniprot ID Interaction Type Evidence Reference
ANGEL1 angel homolog 1 (Drosophila) 23357 Q9UNK9 IP; LC-MS/MS
Huttlin EL , et al. 2015
CHD8 chromodomain helicase DNA binding protein 8 57680 Q9HCK8 ChIP-chip
Subtil-Rodrguez A , et al. 2013
DDX6 DEAD (Asp-Glu-Ala-Asp) box helicase 6 1656 P26196 IP/WB; in vitro binding assay
Wang Y , et al. 2015
EIF3B eukaryotic translation initiation factor 3, subunit B 8662 P55884 IP/WB
Harris TE , et al. 2006
EIF3F eukaryotic translation initiation factor 3, subunit F 8665 O00303 IP; MS; COMPASS
Sowa ME , et al. 2009
EIF4A1 eukaryotic translation initiation factor 4A1 1973 P60842 Affinity chromatography
Connolly E , et al. 2006
EIF4A1 eukaryotic translation initiation factor 4A1 1973 P60842 IP; LC-MS/MS
Huttlin EL , et al. 2015
EIF4A2 eukaryotic translation initiation factor 4A2 1974 Q14240 IP; MS
Ewing RM , et al. 2007
EIF4EBP1 eukaryotic translation initiation factor 4E binding protein 1 1978 Q13541 Y2H
Corominas R , et al. 2014
EIF4EBP1 eukaryotic translation initiation factor 4E binding protein 1 1978 Q13541 Y2H; bimolecular fluorescence complementation assay
Rolland T , et al. 2014
EIF4EBP1 eukaryotic translation initiation factor 4E binding protein 1 1978 Q13541 IP; LC-MS/MS
Huttlin EL , et al. 2015
EIF4EBP1 eukaryotic translation initiation factor 4E binding protein 1 1978 Q13541 GST
Mader S , et al. 1995
EIF4EBP2 eukaryotic translation initiation factor 4E binding protein 2 1979 Q13542 Y2H
Corominas R , et al. 2014
EIF4EBP2 eukaryotic translation initiation factor 4E binding protein 2 1979 Q13542 Y2H; bimolecular fluorescence complementation assay
Rolland T , et al. 2014
EIF4EBP2 eukaryotic translation initiation factor 4E binding protein 2 1979 Q13542 ITC; NMR spectroscopy
Bah A , et al. 2014
EIF4EBP2 eukaryotic translation initiation factor 4E binding protein 2 1979 Q13542 IP; LC-MS/MS
Huttlin EL , et al. 2015
EIF4EBP2 eukaryotic translation initiation factor 4E binding protein 2 1979 Q13542 GST
Mader S , et al. 1995
EIF4EBP3 eukaryotic translation initiation factor 4E binding protein 3 8637 O60516 Y2H
Corominas R , et al. 2014
EIF4EBP3 eukaryotic translation initiation factor 4E binding protein 3 8637 O60516 Y2H; bimolecular fluorescence complementation assay
Rolland T , et al. 2014
EIF4EBP3 eukaryotic translation initiation factor 4E binding protein 3 8637 O60516 Affinity chromatography; IP/WB
Poulin F , et al. 1998
EIF4ENIF1 eukaryotic translation initiation factor 4E nuclear import factor 1 56478 Q9NRA8 Affinity chromatography; IP/WB
Dostie J , et al. 2000
EIF4ENIF1 eukaryotic translation initiation factor 4E nuclear import factor 1 56478 Q9NRA8 Y2H
Corominas R , et al. 2014
EIF4ENIF1 eukaryotic translation initiation factor 4E nuclear import factor 1 56478 Q9NRA8 Y2H; bimolecular fluorescence complementation assay
Rolland T , et al. 2014
EIF4ENIF1 eukaryotic translation initiation factor 4E nuclear import factor 1 56478 Q9NRA8 BioID
Nishimura T , et al. 2015
EIF4ENIF1 eukaryotic translation initiation factor 4E nuclear import factor 1 56478 Q9NRA8 IP; LC-MS/MS
Huttlin EL , et al. 2015
EIF4G1 eukaryotic translation initiation factor 4 gamma, 1 1981 Q04637 IP; LC-MS/MS
Huttlin EL , et al. 2015
EIF4G1 eukaryotic translation initiation factor 4 gamma, 1 1981 Q04637 GST; IP/WB
Mader S , et al. 1995
EIF4G2 eukaryotic translation initiation factor 4 gamma, 2 1982 P78344 GST; IP/WB
Gradi A , et al. 1998
KANK2 KN motif and ankyrin repeat domains 2 25959 Q63ZY3 Y2H
Corominas R , et al. 2014
KANK2 KN motif and ankyrin repeat domains 2 25959 Q63ZY3 Y2H; bimolecular fluorescence complementation assay
Rolland T , et al. 2014
MKNK1 MAP kinase interacting serine/threonine kinase 1 8569 Q9BUB5 IP/WB; Metabolic labeling with 32P
Pyronnet S , et al. 1999
PML promyelocytic leukemia 5371 P29590 GST
Cohen N , et al. 2001
STUB1 STIP1 homology and U-box containing protein 1, E3 ubiquitin protein ligase 10273 Q9UNE7 IP/WB
Murata T and Shimotohno K 2006
TDO2 tryptophan 2,3-dioxygenase 6999 P48775 Y2H
Corominas R , et al. 2014
TDO2 tryptophan 2,3-dioxygenase 6999 P48775 Y2H; bimolecular fluorescence complementation assay
Rolland T , et al. 2014
TRIM27 tripartite motif-containing 27 5987 P14373 Y2H
Corominas R , et al. 2014
TRIM27 tripartite motif-containing 27 5987 P14373 Y2H; bimolecular fluorescence complementation assay
Rolland T , et al. 2014
UBXN11 UBX domain protein 11 91544 Q5T124 Y2H
Corominas R , et al. 2014
UBXN11 UBX domain protein 11 91544 Q5T124 Y2H; bimolecular fluorescence complementation assay
Rolland T , et al. 2014
YBX1 Y box binding protein 1 4904 P67809 IP/WB; in vitro binding assay
Wang Y , et al. 2015
CYFIP1 Cytoplasmic FMR1-interacting protein 1 20430 Q7TMB8 GST; IP/WB
Napoli I , et al. 2008
FMR1 fragile X mental retardation 1 14265 P35922 IP/WB
Napoli I , et al. 2008
park park 40336 Q7KTX7 GST
Ottone C , et al. 2010

HELP
Copyright © 2017 MindSpec, Inc.